Efficacy and Safety of Cyclopentolate Microdrops for Cycloplegic Refraction in Children
Launched by ARISTOTLE UNIVERSITY OF THESSALONIKI · Mar 14, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to use cyclopentolate, a common eye drop used to help measure how well children see when their eyes are relaxed. The researchers want to find out if using smaller drops, called microdrops, works just as well as the standard way of giving these drops. They will also check if there are any side effects from using the microdrops compared to the standard drops.
Children aged 4 to 16 who need these eye measurements for regular eye check-ups at a specific hospital in Northern Greece may be eligible to participate. To join the study, children must be able to cooperate during the eye tests and should not have any known allergies to cyclopentolate or other ingredients in the drops. Participants can expect to receive either the microdrops or the standard drops during their eye exam, and the researchers will follow up to see how they respond. This study is currently looking for volunteers to help answer these important questions about eye care in children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 4-16 years old, who require cycloplegic refraction measurements in the context of regular ophthalmological examination as outpatients in the 2nd Department of Ophthalmology of AUTh at a tertiary center in Northern Greece.
- Exclusion Criteria:
- • 1. Inability for the child to cooperate with autorefractometer
- • 2. Difficulties for the family to attend the follow-up visit
- • 3. Known allergic reaction to cyclopentolate or to any of the other ingredients of this solution
- • 4. Presence of any contraindication for the child to receive cyclopentolate eyedrops (e.g. neurological disease of concern)
About Aristotle University Of Thessaloniki
Aristotle University of Thessaloniki (AUTH) is a prestigious institution in Greece, renowned for its commitment to advancing knowledge and innovation in the field of clinical research. As a leading academic sponsor of clinical trials, AUTH leverages its extensive resources and expertise to conduct rigorous studies that contribute to the understanding of various medical conditions and the development of novel therapeutic interventions. The university fosters collaboration among multidisciplinary teams, ensuring adherence to the highest ethical standards and regulatory requirements while promoting scientific excellence and enhancing patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Thessaloniki, , Greece
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported